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Prevention and Treatment of Hemorrhagic Cystitis 
Nina J. West, Pharm.D. 
Hemorrhagic cystitis is a syndrome associated with certain disease states as 
well as exposure to drugs, viruses, and toxins. It manifests as diffuse bleeding 
of the endothelial lining of the bladder. Treatment includes intravesical, 
systemic, and nonpharmacologic therapies, all of which have advantages and 
disadvantages. 
(Pharmacotherapy 1997; 17(4):696-706) 
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Summary 
Hemorrhagic cystitis is a syndrome of diffuse 
bleeding of the endothelial lining of the bladder. 
The majority of cases are associated with drug 
therapy, but other causes must be ruled out to 
ensure the best response to treatment. Although 
the incidence is low when appropriate 
prophylaxis and monitoring are employed, the 
syndrome is associated with high morbidity. 
Therefore, clinicians should be familiar with 
available treatments and implement them 
immediately on diagnosis. Therapy options 
range from simple, nontoxic procedures to more 
invasive methods that are associated with severe 
adverse effects. 
Background 
Hemorrhagic cystitis results from an assault on 
the bladder wall by toxins, viruses, irradiation, 
drugs, or disease (Table 1). Cyclophosphamide 
is the drug most frequently implicated in the 
syndrome. Damage to the bladder wall is due to 
contact with the acrolein metabolite of 
cyclophosphamide, which causes sloughing, 
thinning, and inflammation of the e~i the1ium.l~ 
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Table 1. Causes of Hemorrhagic Cystitis 
General Cause Specific Cause 
Drugs 
Diseases 
Viruses 
Toxins 
Anabolic steroids 
Busulfan 
Cyclophosphamide 
Ifosphamide 
Immune agents 
Methenamine maleate 
Thiotepa 
Carcinoma 
Amyloidosis 
Rheumatoid arthritis 
Adenovirus 
BK virus 
Cytomegalovirus 
Herpes simplex virus 
Influenza A 
JC virus 
Papovavirus 
Dyes 
Insecticides 
Turpentine 
Radiation therapy 
Adapted from references 1-10, 
Symptoms may arise during therapy or several 
days or months afterward. Bleeding most 
commonly occurs soon after administration of 
high-dose intravenous cyclophosphamide or 
after long-term therapy (several months) of 
smaller oral dosages. Factors that affect the risk 
of developing hemorrhagic cystitis are rate of 
infusion, route of administration, dose, and rate 
of metabolism of cyclophosphamide, as well as 
the hydration status, urine output, frequency of 
emptying the bladder, and concurrent exposure 
to other urotoxic drugs or irradiation.lt3 
If no means of prevention are taken, the incidence 
of cyclophosphamide-induced hemorrhagic cystitis 
is 40-60%. When 2-mercaptoethane sulfonate 
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(mesna) is given as prophylaxis, the incidence is 
decreased to approximately 5%.5 The incidence 
associated with high-dose cyclophosphamide 
after bone marrow transplantation is 8-27Ok.l 
The rate of mortality from uncontrolled 
hemorrhagic cystitis has been reported as 4%.2 
Radiation therapy for treating genitourinary 
malignancies can inflict damage to the bladder 
that is cumulative with repeat treatments. 
Patients who receive concurrent cyclo- 
phosphamide therapy or who have an infection 
are at added risk. As with postchemotherapy 
toxicity, the bladder may become edematous, 
erythematous, and ne~rot ic .~  
Patients with autoimmune diseases (e.g., 
rheumatoid arthritis) occasionally develop 
hemorrhagic cystitis, most commonly after long- 
term oral administration of cyclophosphamide. 
Cases secondary to amyloidosis have been 
reported as Other chronic diseases such as 
carcinoma of the bladder and necrotizing 
vasculitis may also manifest as ~yst i t is .~,  6 ,  
Viruses, including adenovirus, BK virus, and 
cytomegalovirus, can infect the bladder wall and 
induce the di~order.~. w0 This usually occurs in 
immunocompromised populations such as 
patients who have undergone bone marrow 
transplantation. The patient may first develop 
viremia, which spreads to the urine where i t  
comes in contact with the bladder wall. Another 
pathway of infection is retrograde colonization 
through the urethra. In the case of adenovirus, 
the original source may be stool, and the virus 
may spread from the gastrointestinal tract 
through the pelvic lymph system.* 
The clinical diagnosis of hemorrhagic cystitis is 
based on  nonspecific symptoms, such as 
hematuria, dysuria, urgency, and increased 
frequency of urination. Urinalysis reveals large 
cells with hyperchromatic, oversized nuclei with 
oddly shaped cytoplasm, and microscopic 
hematuria.2y The diagnosis can be confirmed by 
cystoscopy. Damage ranges from minor 
telangiectatic bleeding to diffuse necrotic 
ulceration. When severe, the syndrome may lead 
to constriction of the bladder, anemia, recurrent 
urinary tract infections, hydronephrosis, bladder 
perforation, renal failure, and death." 
Prevention 
Several methods are available to reduce the risk 
of cyclophosphamide-induced hemorrhagic 
cystitis, including intravenous hydration with 
diuresis, concurrent intravenous administration 
of mesna, and frequent voiding or bladder 
catheterization with irrigation.l22 l3 The goal is to 
reduce the time the toxins are in contact with the 
bladder wall. Intravenous hydration should 
begin begin 12-24 hours before administration of 
intravenous cyclophosphamide a t  a rate of 
approximately twice that of maintenance, and 
should be continued for 24-48 hours after 
c o mp 1 e t i o n of c y c 1 o p h o sp ha mi d e therapy. 
Diuretics such as furosemide are administered if 
urine production declines (< 100 ml/m2/hr). 
Mesna is administered at  10O-16O0k of the daily 
cyclophosphamide dose by continuous infusion, 
or divided into four doses given intermittently 
beginning 15-30 minutes before the start of 
cyclophosphamide infusion. Some clinicians 
give continuous bladder irrigation of normal 
saline 250-1000 mVhour to facilitate removal of 
toxins from the bladder. However, the presence 
of the catheter carries a risk of infection and local 
trauma. When bladder catheterization is not 
employed, the patient should be required to 
urinate every 2-4 hours. 
The success of mesna as a uroprotectant after 
high-dose cyclophosphamide was compared with 
that of hyperhydration with forced diuresis or 
bladder irrigation in  several trials, mostly 
involving patients undergoing bone marrow 
transplantation. 14-22 In prospective comparisons 
of mesna with forced diuresis, patients in the 
mesna group had less macrohematuria, 13% 
versus 35%19 and 11% versus 44%, respectively.22 
In a similar comparison, mesna administered at 
160% of the cyclophosphamide dose was 
compared with 3 L/m2 of fluid daily with 
intravenous furosemide for low urine 0utput.l' 
Severe hemorrhagic cystitis (passage of clots, 
persistent macrohematuria, need for medical 
intervention) was more common in the mesna 
group (10% vs 6%), and the frequency of either 
severe or consistent hematuria was 33% in the 
mesna arm versus 20% in the hydration arm. 
The authors concluded that there is no  
significant difference in efficacy between the two 
methods. 
A randomized trial in 200 patients compared 
continuous bladder irrigation with continuous 
intravenous mesna at  100% of the 
cyclophosphamide dose. l6 All patients also 
received hyperhydration. Overall, the frequency 
of hematuria in the bladder irrigation group was 
76% and 53% in the patients who received 
mesna. However, the frequency of severe 
hematuria was the same (18%), and the 
investigators resolved that the methods were 
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Table 2.  Treatment of Hemorrhagic Cystitis 
Therapy Administration Duration Advantages Disadvantages 
Until urine is clear. No adverse effects. Not effective as monotherapy Normal saline 
Alum 
Prostaglandins 
Silver nitrate 
Estrogens 
Formalin 
Phenol 
Vasopressin 
Aminocaproic 
acid 
Continuous bladder 
1% solution continuous 
irrigation 
bladder irrigation 
PGEl375-750 pg 
Carboprost tromethamine 
0.1-0.8 mg% instilled into 
bladder daily, dwell 
time 1-4 hrs 
instilled into bladder, 
dwell time 10-20 min 
5 mg p.o./day, with or 
without 1 mg/kg i.v. 
b i d .  for first 2 days of 
therapy 
1-10% solution instilled 
into bladder, dwell 
time 5-30 min 
Bladder instillation of 
100% solution 
Dwell time 1 min 
Continuous i.v. 
0.5-1 .O% solution 
infusion at 0.4 U/min 
5 g i.v. q6h, then 
300 mg/kg/day p.0. or 
continuous bladder 
irrigation (12 a) at 
50 mVhr 
in severe hemorrhagic cystitis. 
Until urine is clear. Mild adverse effects, Recurrence common, 
no anesthesia aluminum toxicity rare. 
required. 
effects, no anesthesia 
required. 
4-7 days. Very few adverse Expensive, close monitoring 
required, uncertain efficacy. 
Single application, Patients may respond Short duration of response, 
repeat if no after failing other anesthesia required, limited 
response. therapies. data in literature. 
Until bleeding Easily administered. Increased risk of cardiovascular 
ceases: 7-10 days. complications, limited data 
in literature. 
Single application, 
repeat if no 
response. 
Single application. 
Until bleeding 
ceases. 
Until bleeding 
ceases. 
Successful response Anesthesia required,'painful, 
common. risk of vesicoureteral reflux. 
Used in refractory Limited data in literature. 
hemorrhagic cystitis. ' 
Used in refractory Limited data in literature, 
hemorrhagic cystitis. systemic adverse effects, 
Limited data in literature, 
hemorrhagic cystitis. systemic adverse effects, 
limited duration of response. 
Used in refractory 
limited duration of response. 
equally effective in this patient population. Thus 
the method of uroprotection-mesna admin- 
istration, bladder irrigation, or hyperhydration 
with forced diuresis-depends on the preference 
of the clinician. 
Treatment 
Supportive Care 
Treatment begins by discontinuing the 
offending agent. Fluid intake should be 
increased to hydrate the bladder and dilute the 
urinary concentration of the toxin. To decrease 
the amount of blood loss, the platelet count 
should be kept above 50,000/mm3. Local 
symptoms may be relieved by administration of 
antispasmodics (oxybutinin or belladonna- 
opium) and narcotic analgesics. If hematuria 
does not  improve or resolve, intravesical 
treatment should be initiated. 
Intravesical Therapy 
Several agents may be administered directly 
into the bladder to achieve local activity and 
avoid systemic toxicity (Table 2). Different rates 
of success have been reported in small patient 
populations or as case reports. No controlled 
studies have evaluated or compared the regimens. 
Adverse effects occur with each method, and in 
some cases, general anesthesia is required. 
Bladder Irrigation 
First-line therapy for hemorrhagic cystitis is 
placement of a large-bore urethral catheter and 
instituting saline lavage.2* This will decompress 
the bladder and remove existing clots. If lavage 
does not free the clots, they must be visualized 
and freed manually with the aid of a resectoscope 
placed under anesthesia. Subsequent therapy is 
much more effective if the bladder wall is free of 
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Table 3.  Preparation of Alum Irrigation Solution 
Steps Example 
Weigh out desired amount of 
powdered alum USP 
(ammonium or potassium 
aluminum sulfate). 
Dissolve in appropriate amount 
of sterile water for irrigation 
USP for a 10% solution. 
Heat the mixture until boiling 
and completely dissolved. microwave. 
Filter solution through a 
0.22-1.1 filter. filter. 
Add aliquot of filtered solution 
to sterile water for final 
concentration of 1% in a 
laminar air flow environment. 
100 g 
900 ml, then add a 
quantity sufficient to 
yield 1000 ml. 
Use hot plate or 
Use hyperalimentation 
Remove 100 ml from 1-L 
bottle of sterile water 
and add 100 ml of 
filtered solution. 
Adapted from reference 24. 
debris. Once the lavage returns as a light pink or 
clear fluid, continuous bladder irrigation with 
normal saline should begin. If bleeding persists 
or worsens, treatment should be advanced to 
administration of another intravesical agent. 
Alum 
Alum (aluminum potassium sulfate or 
aluminum ammonium sulfate) has astringent 
activity on the bladder wall. I t  hardens the 
capillary endothelium, inhibiting the mobility of 
proteins. The urothelium contracts and becomes 
blanched, resulting in decreased local edema and 
inflammati~n.’~ Alum acts only on the surface of 
endothelial cells and in the interstitial spaces. It 
has very low permeability into cells and little 
chance of systemic absorption.’ 
Alum is available as a powder that must be 
dissolved and diluted in sterile water (Table 3).’ 
A final concentration of 1% is most commonly 
used and may be increased to 2% or 4% to 
achieve better r e ~ p o n s e . ’ ~  The solution is 
administered as continuous irrigation through a 
three-way Foley catheter at a rate of 300-1000 
ml/hour. When the appropriate rate is 
administered, the fluid that drains out through 
the catheter will be light pink to clear. The 
response is best when the bladder is evacuated of 
blood clots before alum therapy so that more of 
the bladder mucosa is exposed. 
Many case reports describe treatment of 
hemorrhagic cystitis with alum.23, 25-28 Fifteen 
patients, most of whom had bladder carcinoma, 
received alum 1% by continuous bladder 
irrigation.26 They required an average of 6 L of 
irrigation over 21 hours (range 3-48 hrs) .  
Complete response (no hematuria) was achieved 
in 10 patients (66%) and a partial response 
(reduced hematuria with no transfusion 
requirement) in 2 (13%). 
Similar results were reported in a prospective 
evaluation of 12 patients who developed vesical 
hemorrhage from bladder carcinoma or radiation 
thera~y.’~ All patients had persistent hematuria 
after clot evacuation and normal saline bladder 
irrigation. They were then treated with 1% alum 
solution 3-10 muminute for an average of 36.5 
hours (range 10-52 hrs) . Six patients (50%) had 
a complete response, four (33%) partial, and 2 
(17%) no response. Success rates in two reports 
Most patients had not responded to normal saline 
irrigation or cauterization. 
Adverse effects attributed to alum therapy 
include suprapubic pain, fever, bladder spasm, 
may be relieved by analgesics and antispasmodics. 
The solution’s low pH of 4.5 may be a reason for 
the local effects. Any attempts to neutralize to a 
physiologic pH will result in precipitation of the 
salt. Precipitation of alum can occur in the 
bladder for this and other reasons, clogging the 
catheter and causing interruptions in therapy. In 
most cases the obstruction can be cleared by 
increasing the flow rate through the catheter.27 
Allergic reactions were reported’ that required 
discontinuation of therapy. 
A remote but serious risk for which patients 
should be monitored is aluminum toxicity, which 
manifests as encephalopathy, dementia, speech 
disorders, and seizure. It is assumed to arise due 
to increased systemic absorption. I t  is very 
unlikely for blood concentrations to reach a 
dangerous level in the average patient. However, 
serum aluminum levels should be measured in 
patients with marked renal d y ~ f u n c t i o n ~ ~ ~  31 or 
those who have received prolonged alum therapy 
(several days or longer) and experience central 
nervous system symptoms. 
Advantages of alum therapy include no need 
for anesthesia and low incidence of toxicity. 
However, the cessation of bleeding is rarely 
permanent, lasting only while the therapy is 
being administered. In addition, the precipitate 
that develops in the bladder can clog the catheter, 
causing mechanical difficulties.’ 
involving 13 patients ranged from 50-100 o h. 27, 28 
and urinary retention or freq~ency.’~. 25-29 Th eY 
Prostaglandins 
Prostaglandins (PG)El, EL, and F2 are natural 
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products of the kidneys and bladder. Release of 
these substances from the mucosa is regulated by 
glutathione, which is a membrane protectant. 
The production of prostaglandins is reduced 
when the bladder is distended, in conditions 
such as diabetes mellitus, with disruption of 
normal urine pH and osmolality, and after 
contact with carcinogens.2 
Prostaglandins heal a damaged bladder by 
repairing the microvasculature and epithelium by 
several r n e ~ h a n i s m s . ~ ~ - ~ '  In general, cell 
membranes are strengthened in the presence of 
prostaglandins, and edema resolves. These 
substances may also stimulate platelet 
aggregation and cause local vasoconstriction, 
leading to decreased hematuria. Specifically, 
PGF2 mediates contractility of smooth muscle, 
which may control bleeding, and PGE2 has 
cytoprotective action, which may prevent further 
damage to the bladder wall. 
Carboprost tromethamine, a synthetic 
derivative of PGF2, is administered as a solution 
of 0.1-0.8 mg/dl. It is instilled into the bladder 
and allowed to dwell for 1-4 hours.  This 
procedure is repeated 3-4 times/day unt i l  
bleeding subsides, generally in 5-7 days. 
In the largest series reported, 24 patients 
developed hemorrhagic cystitis within 180 days 
after bone marrow t r a n ~ p l a n t a t i o n . ~ '  The 
syndrome did not respond to hydrocortisone 
bladder irrigation and platelet transfusions. After 
evacuation of clots from the bladder, carboprost 
tromethamine in 50 ml saline was instilled for 60 
minutes every 6 hours.  Between doses, 
continuous irrigation with 0.02% hydrocortisone 
was administered. Eleven patients participated in 
the first phase. The initial carboprost dose was 
0.2 mg/dl and was increased by 0.2 mg/dl 
oncdday (maximum 1 mg/dl) until a complete 
response was achieved. Treatment was 
discontinued after 48 hours of the effective dose, 
or a maximum of 14 days. Thirteen patients 
participated in the second phase, which called for 
an initial dose of 0.8 mg/dl with gradual increases 
to 1.0 mg/dl after four doses. Therapy was 
continued for 48 hours after hematuria resolved 
or for 7 days One patient dropped out due to an 
unrelated illness. Fifteen patients (65%) 
responded, one each at doses of 0.4 and 0.6 
mg/dl, seven (30%) at 0.8 mg/dl, and six (26%) at 
1.0 mg/dl. Within 17 days (median 7 days) nine 
patients had a recurrence of hematuria, one 
responded to another course of carboprost, four 
responded to other treatments, and four had no 
response. 
In another report, eighteen patients, the 
majority of whom had undergone bone marrow 
transplantation, developed hemorrhagic cystitis 
due to cyclophosphamide therapy.33 Before 
receiving PGF2, each subject failed treatment 
with normal saline bladder irrigation or diuresis 
and required at  least 1 U packed red blood 
cells/day, or  had undergone several clot 
evacuation procedures. Urine viral cultures were 
negative in  all patients, and therefore 
cyclophosphamide was presumed to be the only 
cause of hemorrhagic cystitis. After evacuating 
existing blood clots, the patients were given a 50- 
ml instillation of carboprost tromethamine 
0.2-0.8 mg/dl for 2 hours 4 timedday. They 
received a total dose of 3.6-15.8 g over 2-7 days 
(median 6 days). Nine patients (50%) achieved a 
complete response after 7 days of therapy. A 
partial response, with treatment for longer than 7 
days, was seen in eight patients, and there was 
one nonresponder. Bladder spasm occurred in 14 
patients bu t  was ' well controlled by 
administration of oxybutinin. There were no 
systemic side effects. 
The authors  concluded that carboprost 
tromethamine is an effective treatment with low 
morbidity compared with alternative therapies. 
They noted that patients who responded poorly 
were more thrombocytopenic and required more 
packed red blood cell transfusions than the other 
subjects. Of those who had a bone marrow 
transplant, patients treated on an allogeneic 
protocol fared worse than those who received an 
autologous graft. 
Several trials reported successful treatment 
with PGEl and P G E z . ~ ~ ,  36, 40 Six children who 
developed hemorrhagic cystitis from 
cyclophosphamide with or without radiation 
therapy received intravesical PGEl 750 pg in 100 
ml with a dwell time of 1 hour/day for at least 7 
days.35 Five patients responded with complete 
elimination of gross hematuria within 7 days. 
Results were more favorable in 10 patients who 
had viral-induced hemorrhagic cystitis after bone 
marrow tran~plantation.~' Prostaglandin E2 0.75 
mg in 200 ml normal saline was instilled and left 
to dwell for 4 hours. Hematuria resolved within 
24 hours in 40% of patients, with a median time 
for all patients of 5 days. 
Adverse effects from parenterally administered 
prostaglandins include pyrexia, vomiting, 
diarrhea, nausea, flushing, chills, and cough. 
Fortunately, local instillation of prostaglandins is 
associated only with bladder spasm and 
discomfort due to the distended bladder. Patients 
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can tolerate the treatment even i f  they are 
medically unstable,32 and antispasmodics and 
analgesics relieve the side effects. 
This intravesical therapy is costly, and although 
it  is easily administered at the bedside without 
anesthesia, the patient must have intensive 
nursing care for instillation and drainage. Unlike 
alum, prostaglandins form no precipitate that 
may clog the catheter. However, the appropriate 
dosage for a reliable response has not been 
determined and further investigation is indicated. 
Silver Nitrate 
Silver nitrate coagulates proteins on the 
bladder mucosa, resulting in  a cauterizing 
action.2. 41 A 0.5-1.0% solution is instilled and 
remains in the bladder for 10-20 minutes; this 
may be followed by normal saline irrigation to 
flush out the bladder.2 The procedure is painful, 
and the patient must be anesthetized. 
In the largest report of this therapy, 10 children 
developed hemorrhagic cystitis 8 weeks-2.5 years 
after receiving cyclophosphamide, with or 
without radiation therapy.42 Nine of them 
continued to require transfusions after failing 
such therapies as aminocaproic acid, saline 
irrigation, and intravesical steroids. The patients 
underwent cystoscopy, blood clot evacuation, and 
normal saline irrigation. Silver nitrate 0.5-1.0% 
was instilled for 10-15 minutes, after which 
saline bladder irrigation was given for 24-48 
hours. Bleeding was completely controlled in 
90% of patients within 24-48 hours. One patient 
failed to respond to the first course and was 
treated with phenol instead. Eight patients 
experienced 12  episodes of recurrence that 
appeared 1 day-2 years afterward and responded 
to repeat administration of silver nitrate. Bladder 
spasm occurred in three patients and subsided 
after treatment with meperidine and 
hydroxyzine. 
A serious adverse effect that was reported in 
one patient after silver nitrate therapy is anuria. 
The patient developed significant obstruction of 
the ureters and collecting ducts due to crusty 
build-up that was thought to have arisen from 
the precipitation of silver nitrate to silver 
chloride.41 The authors  recommended 
performing cystoscopy before silver nitrate 
therapy to become familiar with the anatomy. If 
the bladder is too severely damaged, precipitation 
is likely due to an increased tendency of 
precipitate to form on ulcerated surfaces. The 
authors also advocated avoiding sodium chloride 
irrigation to lower the risk of precipitation. This 
severe reaction has not  been reported 
subsequently, therefore the standard of practice 
for silver nitrate treatment does not preclude 
saline irrigation. 
One patient developed ileus, abdominal pain, 
and tenderness after silver nitrate in~t i l la t ion.~~ It 
was believed that silver nitrate extravasated and 
precipitated in the perinephric area. The patient 
underwent surgical diversion of the left ureter. 
Routine performance of an excretory urogram 
and a voiding cystogram is recommended to 
identify patients at risk for developing such 
severe reactions. 
The success of silver nitrate application is 
variable and and the duration of response is often 
short. Also, the risks of the anesthesia must be 
taken into account when considering this 
treatment option. 
Formalin 
Formalin is the aqueous form of formaldehyde. 
I t  exerts its effect on  the bladder wall by 
hydrolyzing protein, thereby coagulating tissue 
and controlling bleeding in  the mucosa and 
submucosa. Cross-linking of proteins helps 
prevent further necrosis, sloughing, and blood 
loss.2, 44 Formalin solution is diluted with sterile 
water to a concentration of 1-10%. It is instilled 
into the bladder at a volume of 50 ml or bladder 
capacity under general or local anesthesia and 
allowed to dwell for 5-30 m i n ~ t e s . ~ ~ - ~ O  
Anesthesia is required because contact of 
formalin with the bladder wall causes significant 
pain. 
One group reviewed all the reports of patients 
who received treatment with formalin for 
hemorrhagic ~ystitis.~' Of the 235 patients, 123 
were treated with lo%, 91 with 5% (range 3-6%), 
and 21 with 1% (range 1-2%) solution. In most 
of them the bladder was filled to capacity under 
gravity. Complete response, defined as resolution 
of hematuria after one course of therapy, was 
83%, 78%, and 71% in patients treated with 
solutions of lo%, 5%, and 1%, respectively. The 
average dwell time was 12, 23, and 14 minutes 
for the three solutions. The average duration of 
response was 3-4 months. 
Complications were considered minor if no 
surgical intervention was required; these were 
fever, tachycardia, urinary frequency or urgency, 
elevated blood urea nitrogen or creatinine 
concentration, mild hydronephrosis, grade 1-11 
vesicoureteral reflux, incontinence, suprapubic 
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pain, or decreased bladder capacity not requiring 
urinary diversion. If surgery was necessary, the 
complication was classified as major; these were 
anuria, acute tubular necrosis, papillary necrosis, 
ureteral or retroperitoneal fibrosis, ureterovesical 
or ureteropelvic junction obstruction, severe 
hydronephrosis, grades 111-IV vesicoureteral 
reflux, any vesical fistula, and decreased bladder 
capacity requiring bladder diversion. Minor 
complications occurred in approximately 15% of 
patients receiving 1% solution, but increased to 
35% for the 5% solution, and were significantly 
more frequent--80%-for the 10% solution. 
Major complications were also more frequent at 
higher concentrations, but the differences were 
not  statistically significant. Patients with 
hemorrhagic cystitis from radiation treatment of 
bladder cancer responded best to the 10% 
solution. However, in those who developed 
hemorrhagic cystitis from cyclophosphamide or 
unresected bladder cancer, better results were 
produced with solutions in the 5% range. 
Of 25 patients who were treated with formalin 
10% or 4% solutions with dwell times of 5-15 
minutes,  88% achieved a good response 
(hemodynamic stability) .59 After 4 months, there 
were four cases of recurrence. In 35 patients who 
received formalin 1%, 2%, or 4% over 20-30 
minutes, complete response was observed in 
86%, 90%, and 75%, respe~tively.~~ Recurrence 
was most frequent after treatment with 1% 
formalin (23%), as opposed to 0% and 2% with 
4% and 2% solutions,  respectively. Major 
complications (bilateral hydroureteronephrosis, 
vesicovaginal fistula, decreased bladder capacity 
requiring diversion, death) were more frequent 
with 4% (100%) than with 1% or 2% formalin 
(13.6% and 40%, respectively). The authors 
recommended the 1% solution since it is as 
efficacious as higher concentrations and 
associated with fewer severe adverse effects. 
The greatest danger with formalin is 
vesicoureteral reflux, which may result i n  
ureteral obstruction or hydronephrosis. Patients 
often undergo a cystogram before therapy to 
evaluate the risk of reflux. Then a balloon is 
placed and inflated to occlude passage of the 
drug into the ureter during treatment. Placing 
the patient in the reverse Trendelenburg position 
is also effective in preventing reflux. The risk of 
significant damage outside the bladder is 
decreased by lowering the concentration of the 
solution and by shortening the dwell time. 
Limiting the number of repeat instillations will 
also decrease the risk. 
Phenol 
Intravesical administration of phenol can 
successfully cause chemical cauterization in 
patients with hemorrhagic cystitis. A 12-year-old 
child with cyclophosphamide-induced 
hemorrhagic cystitis was treated with this agent.61 
Thirty milliliters of 100% phenol was combined 
with 30 ml glycerin, painted across the surface of 
the bladder, and suctiohed out after 1 minute of 
contact. Then alcohol 60 ml was instilled and 
suctioned out after 1 minute. Finally, the bladder 
was irrigated with saline. The patient died of 
infection within 6 months of treatment but had 
no recurrence of hematuria. 
As with other methods of cauterization, the 
effects of phenol can be short-lived and 
anesthesia is required. It is possible, that the 
frequency of fibrosis in the bladder is less than 
that with formalin therapy2, 3 4 v  
Systemic Agents 
Systemic treatment is reserved for cases that 
are refractory to intravesical therapy. The 
literature contains few reports of these agents, 
and, as with intravesical therapy, no controlled 
trials have been conducted. General anesthesia is 
not a concern with this mode of treatment; 
however, since exposure is more than local, 
patients are at  risk of developing systemic 
adverse effects associated with the drugs. 
Conjugated Estrogens 
Conjugated estrogens appear to control 
hematuria by strengthening the capillary walls of 
the microvasculature in the bladder mucosa.62 
Five patients who developed hemorrhagic cystitis 
due to radiation or cyclophosphamide therapy 
were treated with the agents.63 Two received 1 
mg/kg intravenously twice/day for 2 days, 
followed by 5 mg/day orally for several months. 
The remaining three received only the oral 
regimen. In four patients, the urine was clear 
within 1-7 days, and no recurrence was seen 
during follow-up of 12-22 months. 
These positive results were replicated in seven 
patients with cyclophosphamide- and radiation- 
induced hemorrhagic cystitis who did not 
respond to formalin, phenol,  or saline 
i r r i g a t i ~ n . ~ ~  They received conjugated estrogens 
2.5 mg orally twice/day. Six subjects had 
complete response with no gross hematuria 
within 10 days of therapy, and one did not 
respond. Other investigators, however, reported 
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failure of estrogens in managing the syndrome.65 
Estrogen therapy increases a patient’s risk of 
cardiovascular complications and should not be 
administered over the long term in patients who 
have a history of thromboembolic events, 
cardiovascular disease, or cerebrovascular disease 
until further studies have been p e r f ~ r m e d . ~ ~  
Vasopressin 
Intravenous infusion of vasopressin lessens 
bleeding into the bladder through direct 
contraction of smooth muscle, resulting in 
vasoconstriction.66 A 15-year-old patient who 
developed hemorrhagic cystitis after bone 
marrow transplantation with cyclophosphamide 
failed treatment with formalin, saline bladder 
irrigation, and silver nitrate, and still required 
blood transfusions.66 Within 1 hour of initiation 
of vasopressin 0.4 U/minute the bleeding 
decreased. However, attempts to wean the 
patient from the infusion resulted in increased 
hematuria. The patient died of other complications. 
Vasopressin may cause severe allergic reactions, 
such as tremor, sweating, vertigo, headache, 
abdominal cramping, urticaria, or bronchial 
constriction. If extravasation occurs, local tissue 
may necrose. The agent should not  be 
administered unless intravesical therapy fails or if 
the patient’s clinical status is so poor that 
immediate cessation of hematuria is necessary. 
Aminocaproic Acid 
Systemic aminocaproic acid can decrease blood 
loss by inhibit ing plasminogen activator 
substances, thereby halting fibrinolysis. A 54- 
year-old man who developed hemorrhagic cystitis 
after cyclophosphamide and radiation therapy 
was treated with aminocaproic acid 5 g intra- 
venously every 6 hours for 2 weeks, followed by 
300 mg/kg/day orally.67 Concurrently, he 
received bladder irrigation of aminocaproic acid 
12 g/L at a rate of 50 mlhour. The hematuria 
diminished within 6 hours, and after 24 hours he 
had only microscopic blood loss. 
One danger associated with aminocaproic acid 
is that clots that form in the bladder could be too 
large to pass, resulting in urethral obstruction. 
Systemic administration may cause nausea, 
diarrhea, hypotension, malaise, myopathy, 
dizziness, headache, thrombosis, and rarely, 
grand ma1 seizure. However, like vasopressin, 
this is a useful alternative in the case of life- 
threatening bleeding that is unresponsive to 
intravesical therapy. 
Hyperbaric Oxygen 
In theory, hyperbaric oxygen heals the bladder 
by increasing tissue concentrations of oxygen, 
thereby promoting growth of healthy 
The presence of hyperoxia in the bladder may 
also help decrease bleeding by causing 
vasoconstriction. Patients who failed traditional 
local therapy for hemorrhagic cystitis responded 
when exposed to hyperbaric oxygen.6s72 Thirteen 
patients with radiation-induced hemorrhagic 
cystitis were placed in a hyperbaric oxygen 
chamber for 2 hourslday for 60 days.69 The 
chamber provided 100% oxygen at 2 atm absolute 
pressure. Bleeding resolved permanently in 12 of 
these patients and no adverse effects were seen. 
The complete response rate (elimination of all 
symptoms) was 57% in 14  patients with 
radiation-induced hemorrhagic cystitis who 
received hyperbaric oxygen of 100% at 2.4 
atmospheres absolute for 90 minutes 5-6 
days/week for an average of 28  treatment^.^' 
Adverse effects in these patients were few and 
mild, including myopia, visual changes, and 
middle ear pressure. 
Hyperbaric oxygen may cause harm to the 
body in the form of barotrauma to the ears, toxic 
effects to the brain (e.g., seizures), pneumothorax, 
cataracts, retinal vasoconstriction, stroke, and 
myocardial infarction. However, these effects are 
not likely to occur from the limited exposure 
necessary to control hematuria. This treatment 
modality is not available at all medical centers 
and should be saved for patients who do not 
respond to traditional therapy. 
Cry osurgery 
Another treatment that  is not performed 
frequently is cryosurgery. Patients have benefited 
from direct administration of liquid nitrogen to 
the bladder lesions. This is done for four cycles 
of 2 minutes’ duration. Bleeding was arrested for 
3 months-5 years after this treatment.73 
Nonpharmacologic Interventions 
Invasive methods of controlling hematuria are 
reserved as a last r e ~ o r t . ~ ” ~ ~  They include urinary 
diversion, internal iliac artery embolization, 
unilateral hypogastric artery ligation, and, if all 
else fails, cystectomy.2, 2 5 9  78 T ypes of urinary 
diversions include nephrostomy, ureterostomy, 
ileal loop diversion, cutaneous ureterostomy, and 
ureterosigmoidostomy. Whenever possible, a 
reversible procedure is employed, however, some 
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Ideally, patients at risk of the syndrome are 
identified early, and proper prophylactic 
measures are taken. Once hemorrhagic cystitis 
occurs, the patient should receive intravenous 
hydration and if clots are present, irrigation of 
the bladder is indicated. Patients who fail these 
therapies should be treated with bladder 
irrigations of prostaglandins or alum, followed by 
instillation of silver nikrate and formalin if no 
response is achieved. When these pharmacologic 
treatments provide no relief, surgical options 
such as nephrostomy should be considered. 
patients benefit only from a permanent 
restructuring of the urinary system. 
Percutaneous nephrostomy, the most common 
procedure, diverts urine from the bladder to 
prevent overdistention, which can cause vessels 
to These procedures are reversible; the 
drains can be removed once the bladder is healed 
sufficiently. Potential complications, in addition 
to those generally associated with surgical 
procedures, are perirenal hematoma, occlusion of 
the nephrostomy tube, and pyelonephritis. 
Percutaneous nephrostomy is rarely associated 
with life-threatening complications. It requires 
only local anesthesia and can be repeated safely if 
hematuria recurs. 
Nephrostomy tubes were placed in six patients 
who failed initial therapy and were left in place 
for 3-168 days (mean 68 days).75 Fifty percent of 
subjects had complete resolution of hemorrhage. 
Others reported that 14 of 16 patients with 
intractable hemorrhagic cystitis who underwent 
urinary diversion responded very well and 
suffered no untoward effects.76 Surgical methods 
such as these are not desirable for patients who 
are hemodynamically unstable.2 
The goal of embolization of the internal iliac or 
hypogastric arteries is to prevent blood from 
reaching the bladder, thereby limiting its loss 
through the mucosal wall. The procedure is 
performed under local anesthesia and guided by 
fluoroscopy.2- 77 Six of eight patients who 
underwent internal iliac embolization responded 
well.77 Adverse effects include gluteal muscle 
pain and, in rare cases, paralysis and bladder 
necrosis2 
Additional treatment modalities to control 
bleeding provide symptomatic relief, but the 
duration of response is generally limited. For 
example, direct hydrostatic pressure to the 
bladder wall can be administered by inflating a 
balloon in the bladder to a pressure of 100 cm 
water for 4-6 hours. This technique achieved 
hemostasis i n  three of six patients.79 I t  is 
technically difficult to perform and carries the 
risk of bladder perforation and damage to the 
function of the detrusor muscle.2, 79  Direct 
irrigation with ice was helpful in radiation- 
induced hemorrhagic cystitis, acting as an  
astringent through local cooling.2 Neither of 
these methods is a primary treatment. 
Summary 
Several methods for treating hemorrhagic 
cystitis provide various degrees of response. 
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